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I n 2007, prostate cancer was the fifth ranked cancer among males in Taiwan, with a crude incidence of 29 per 100,000, [1] equivalent to one-fourth and one-sixth of that of the United Kingdom and the United States, respectively. [2, 3] Most patients in the United States are diagnosed in the early stages of the disease; [3] however, in Taiwan, more than 50% of cases are identified in stages T3-4 or with metastatic disease. [4, 5] In a study of radical prostatectomy (RP) in three medical centers in Taiwan, it was discovered that Taiwanese patients were older at the time of surgery and exhibited higher pre-operative prostate-specific antigen (PSA) levels and biochemical failure rates than those reported in studies in the west. [6] Similar findings were reported in another independent study, indicating that Taiwanese prostate cancer patients treated with RP also tended toward an advanced pathological stage, high Gleason scores, and high positive surgical margin rates. [7] Similar findings have also been reported in other Asian countries. [8, 9] These results suggest that the use of radiotherapy (RT) for adjuvant or salvage treatment in high-risk prostate cancer patients following RP might has a more significant impact in Asian countries, including Taiwan, than it does in the west.
Three large randomized studies, SWOG 8794, [10, 11] EORTC 22911, [12] and German ARO 96-02, [13] all demonstrated the benefits of post-RP RT for high-risk patients to improve biochemical progression-free survival (bPFS), and even overall survival (OS) in selected categories. Adjuvant post-RP RT improved the 5-year bPFS from approximately 50-70%. [12, 13] However, 6-year biochemical control by salvage radiation alone for patients with PSA ≧ 0.2 ng/ml (a cut-off value for definition of postoperative biochemical failure) was only 32%. [14] Several studies have reported that the addition of androgen deprivation therapy (ADT) to post-RP RT is beneficial to bPFS. [15] [16] [17] Considering the side effects caused by long-term ADT, further stratification of patients into different risk groups would no doubt facilitate the selection of high-risk patients for ADT.
Prostate cancer patients in Taiwan and other Asian countries are more likely to exhibit indicators for adjuvant or salvage RT following RP; therefore, the aim of this study was to evaluate the outcome of patients receiving adjuvant or salvage RT, and to identify those patients with an elevated risk of biochemical failure following RT.
METHODS
Between May 2001 and December 2008, we reviewed 53 consecutive cases of non-metastatic prostate adenocarcinoma treated with RP followed by RT. Three patients who had been receiving ADT for more than 6 months prior to RT and another patient without pathologic T stage were excluded from the study. Indicators for post-RP RT included pathological risk factors, such as extracapsular extension (ECE), seminal vesicle invasion (SVI), positive resection margin, positive lymph node (LN), increase in detectable PSA levels in at least two subsequent measurements, and biochemical and/or clinical failure. Post-RP biochemical failure was defined as a PSA level ≧ 0.2 ng/ml. Clinical failure was recorded by imaging and proven through pathological analysis.
Doses of RT ranged between 63 and 66.6 Gy for patients receiving adjuvant RT or those not presenting with gross lesions in pre-RT magnetic resonance imaging (MRI) or computed tomography (CT) scans, and 72 Gy for patients with gross tumors. RT was administered at 1.8 Gy/per fraction/day and five fractions per week. The planning target volume (PTV) was generated with a posterior margin of 0.7 cm and with 1 cm margin in all other directions. The radiation to the prostate region was given by intensity-modulated radiotherapy (IMRT), but three-dimensional four-field (anterior-posterior and bilateral opposing) was applied to pelvic irradiation. Pelvic irradiation was administered to patients with N1 disease or ≧ 15% pelvic LN metastasis rate according to the Roach formula of [2/3 PSA + (Gleason score − 6) × 10]. [18] Pelvic RT was omitted for pathological N0 cases, for patients older than 75 years, and for those with severe co-morbidity. ADT was permitted but not standardized.
Follow-up was conducted mainly by serum PSA testing and digital rectal examination (DRE), with imaging studies arranged when necessary. PSA was checked on the day at which RT was completed, and every 3-4 months for the first 2 years, continuing every 4-6 months thereafter. Acute and late adverse events were recorded at each visit to out-patient departments (OPD), focusing mainly on rectal and urinary toxicity. Adverse events persisting for more than 3 months after RT or appearing 3 months after completion of RT were defined as late events. The severity of adverse rectal and urinary events was recorded according to the Common Terminology Criteria for Adverse Events 3.0 (CTCAE 3.0), published by the Cancer Treatment Evaluation Program of the National Cancer Institute (CTEP/NCI).
The primary endpoints for evaluation were the relapse of disease in any form. Survival was measured from the last day of RT using Kaplan-Meier survival calculations. The bPFS time was calculated as the period between the last day of RT and the date of biochemical failure, which was defined as a PSA level ≧ 0.2 ng/ml. The log-rank test was used to determine differences in univariate analysis. Cox proportional-hazards regression analysis was employed in multiple covariate analysis. SPSS for Windows (version 13.0; SPSS Inc., Chicago, IL, USA) was used for all data analyses. The study was approved by the Institutional Review Board of the Chang Gung Memorial Hospital (99-3646B).
RESULTS
A total of 49 patients were eligible for this study, with a median age of 66 years. Median time from RP to RT was 5 months (range 1-71 months). Patient characteristics and distribution of pathologic prognostics are shown in Table 1 . The median RT dose was 66.6 Gy. Twenty-five (51.0%) patients underwent pelvic irradiation. The percentage of patients without ADT, with short-term (≦6 months) ADT, and with long-term (>6 months, or orchiectomy) ADT was 53.1%, 20.4%, and 26.5%, respectively. Among the patients with pre-RT PSA ≧ 0.2, 39.1% had undergone long-term ADT; the corresponding figure was 14.3% for patients with pre-RT PSA < 0.2 ng/ml.
A f t e r a m e d i a n f o l l ow -u p o f 5 3 m o n t h s (range 14-111 months), the 4-year OS and bPFS for all patients were 91.0% and 68.9%, respectively [ Figure 1 ]. Five patients died during the follow-up period, two of whom died of prostate cancer with distant metastases. According to univariate and multivariate analysis, pre-RT PSA was the most significant factor for bPFS [ Table 2 ]. Patients with pre-RT PSA levels of < 0.2 ng/ml and ≧ 0.2 ng/ml had a 4-year bPFS of 83.1% and 52.6%, respectively (p = 0.013) [ Figure 2 ]. Other factors such as Gleason score, pathologic T stage, positive surgical margin, hormone therapy, and pelvic irradiation were not considered independent prognostic factors.
The toxicity profile is shown in Table 3 , and the grading system for rectal and urinary toxicity is shown in Table 4 . The incidence of chronic rectal toxicity was low, with no grade 3 toxicity reported and grade 2 toxicity found in only 6 patients (12.2%). However, long-term urinary toxicity of grade 2 or higher was found in 24 patients (49.0%). When urinary incontinence was considered separately, long-term pad dependence occurred in 36.7% of the total population. A relationship between pre-RT urinary incontinence and long-term pad dependence rate was found. Long-term pad dependence rate was 11.8%, 22.2%, and 85.7%, respectively, Patients with pre-RT PSA levels of < 0.2 ng/ml and ≧ 0.2 ng/ml had a 4-year bPFS of 83.1% and 52.6%, respectively (p = 0.013) (PSA, prostate-specific antigen; bPFS, biochemical progression-free survival, RT, radiotherapy) 
DISCUSSION
This study reports the status of post-RP RT for prostate cancer in Taiwan. Although this is a retrospective study with a limited number of cases, it reveals the poor bPFS of patients with pre-RT PSA ≧ 0.2 ng/ml. In a study of pathologic features following RP, conducted between 1993 and 2001 in Taiwan, [7] pathological T3-4 disease, Gleason score ≧ 7, and positive margin were found in 60%, 91%, and 32% of the patients, respectively, with 56% of the patients exhibiting a PSA level > 10 ng/ml. Immediate failure was observed in 15% of the patients and the median time for the progression of the disease among the remaining patients was 16 months. These pathological and clinical features suggest that Taiwanese patients receiving RP had more advanced disease and earlier failure. In a recent study of 341 patients from three medical centers in Taiwan, this trend continued with biochemical failure found in 37% of the patients following a median follow-up of 31 months. [6] These results show a high rate of biochemical failure occurring within a short follow-up period, making it highly likely that patients receiving post-RP RT in Taiwan suffer from more adverse factors, such as larger residual tumor burden or more aggressive tumor behavior, than the patients in western countries.
In the current study, patients with pre-RT PSA level of < 0.2 ng/ml and ≧ 0.2 ng/ml had a 4-year bPFS of 83.1% and 52.6%, respectively (p = 0.013), suggesting that PSA < 0.2 ng/ml is an important factor in prognosis. These findings are in agreement with those reported in SWOG 8794, which, after a long-term follow-up, showed a better metastasis-free survival in patients with PSA < 0.2 ng/ml, with the 10-year metastasis-free survival for patients with PSA < 0.2 ng/ml and ≧ 0.2 ng/ml of 73% and 65%, respectively. [10] When facing the clinical dilemma of deciding whether to initiate RT for patients with increased PSA but remaining below biochemical failure, we suggest that RT is preferably administered prior to biochemical failure, if long-term disease control is the goal.
Patients receiving post-RP RT exhibited higher acute and chronic toxicity than those treated primary with RT. Acute grade 3 toxicity was 16.3% in this study and 7% in our previous study for patients treated primarily with IMRT. [19] No acute grade 3 toxicity was observed in any patient in this study, treated with prostate implants in conjunction with high-dose-rate (HDR) brachytherapy plus external beam radiotherapy (EBRT). [20] Differences between post-RP RT and primary RT in chronic complication rates were even greater, [19, 20] Corresponding figures for pad dependence were 3% and 0%, respectively. The rates of ≧ grade 2 chronic rectal complications were 12.2%, 4%, and 6% for patients treated by post-RP RT and HDR brachytherapy with EBRT and IMRT, respectively. [19, 20] The complication rates for post-RP RT in this study are considerably higher than those reported in other studies. The overall complication rate in the post-RP RT group was 23.8% in the SWOG 8794 trial and 21.9% in the ARO 96-02 trial. [11, 13] The high rate of urinary complication in this study could be attributed to the close relationship between pre-RT and post-RT urinary function. Only 34.7% of our patients had normal pre-RT urinary function, and 28.6% had grade 2 urinary toxicity prior to RT. It is well known that the maturation of RP technique involves a steep learning curve. [21, 22] Reducing urinary complications is difficult for surgeons in countries with a low incidence of prostate cancer. [23] In this study, PC patients treated by RP were in more advanced stages of the disease, often requiring more radical resection to ensure a negative margin, thereby exacerbating the problem. With regard to the possible impact of RT protocol on chronic urinary toxicity, the given dose and delivery technique remained consistent throughout the study, except for half of the patients receiving pelvic irradiation. However, studies on radical RT have indicated that pelvic irradiation is associated with an increase in rectal, but not urinary toxicity. [24, 25] The retrospective nature and limited number of cases in this study impose considerable limitations on the applicability of these findings. Although all of the patients were treated according to the same principles, the limited number of cases made it difficult to perform analysis based on adjuvant or salvage RT. Nonetheless, this study still showed that for patients with increasing PSA levels following RP, local RT should be administered prior to biochemical failure (PSA ≧ 0.2 ng/ml), to ensure good bPFS. However, post-RP RT involves considerable urinary toxicity, often leading to long-term urinary incontinence.
